The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Long–Term Interleukin 10 Therapy in Chronic Hepatitis C Patients Has A Proviral and Anti–Inflammatory Effect
Open accessAbstract
An imbalance in Th1 and Th2 cytokine production is implicated in disease progression of HCV. Our aim was to determine the effect of IL–10 administration in patients with HCV–related liver disease. Thirty patients with advanced fibrosis who had failed antiviral therapy were enrolled in a 12–month treatment regimen with SQ IL–10 given daily or thrice weekly. Liver biopsies were performed before and after therapy. Serum and PBMC were collected for HCV RNA, ALT, and functional T–cell analysis. IL–10 led to significant improvement in serum ALT (mean ALT: day 0 = 142 ± 17 vs. month 12 = 75 ± 10; P < .05). Hepatic inflammation score decreased by at least 2 in 13 of 28 patients (mean decrease from 4.6 ± 0.3 to 3.7 ± 0.3, P < .05) and 11 of 28 showed a reduction in fibrosis score (mean change from 5.0 ± 0.2 to 4.5 ± 0.3, P < .05). Serum HCV RNA levels increased by 0.5 log during therapy (mean HCV RNA day 0: 12.3 ± 3.0 Meq/mL; 12 months: 38 Meq/mL; P < .05) and returned to baseline at the end of follow–up (11.0 ± 2.4 Meq/ml). Five patients developed viral loads of greater than 120 Meq/mL and two of these developed an acute flare in serum ALT. IL–10 caused a decrease in the number of HCV–specific CD4+ and CD8+ IFN–γ secreting T cells and alterations in PBMC cytokine production towards a Th2 dominant profile. These changes parallel the improvement in ALT and rise in HCV RNA. In conclusion, long–term rIL–10 therapy appears to decrease disease activity, but also leads to increased HCV viral burden via alterations in immunologic viral surveillance. (Hepatology 2003;38:859-868).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544
The role of IL-10 in promoting disease progression in Leishmaniasis
Kane, M. M., & Mosser, D. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1141 · Cited by 514
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
“The severity of liver fibrosis in a subset of patients chronically infected with hepatitis C virus was also reduced by IL-10 treatment [156].”
BackgroundFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera, R., Tu, Z., Xu, Y., Firpi, R. J., Rosen, H. R., Liu, C., & Nelson, D. R. (2004) · Hepatology · doi:10.1002/hep.20454 · Cited by 562
Self-citationSaid, E. A., Dupuy, F. P., Trautmann, L., Zhang, Y., Shi, Y., El-Far, M., Hill, B. J., Noto, A., Ancuta, P., Peretz, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2106 · Cited by 481
Liver regeneration — mechanisms and models to clinical application
Forbes, S. J., & Newsome, P. N. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.97 · Cited by 411
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
Interleukin-10 and the pathogenesis of human visceral leishmaniasis
Nylén, S., & Sacks, D. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.004 · Cited by 374
Sinusoidal communication in liver fibrosis and regeneration
Marrone, G., Shah, V. H., & Gracia-Sancho, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.018 · Cited by 323
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis
Czaja, A. J., & Manns, M. P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.053 · Cited by 280
Fibrosis Related Inflammatory Mediators: Role of the IL‐10 Cytokine Family
Sziksz, E., Pap, D., Lippai, R., Béres, N. J., Fekete, A., Szabó, A. J., & Vannay, Á. (2015) · Mediators of Inflammation · doi:10.1155/2015/764641 · Cited by 265
The two faces of interleukin 10 in human infectious diseases
Mege, J.-L., Meghari, S., Honstettre, A., Capo, C., & Raoult, D. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70577-1 · Cited by 257
Safadi, R., Ohta, M., Alvarez, C. E., Fiel, M. I., Bansal, M., Mehal, W. Z., & Friedman, S. L. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.062 · Cited by 239
Drug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
“Immunosuppressive agents to treat cirrhosis may cause a flare up of the underlying viral hepatitis [170].”
BackgroundRigopoulou, E. I., Abbott, W. G. H., Haigh, P., & Naoumov, N. V. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.06.003 · Cited by 98
Hoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., & Herzog, R. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.33 · Cited by 72
Increased Protein Glycation in Cirrhosis and Therapeutic Strategies to Prevent It
AHMED, N., LÜTHEN, R., HÄUSSINGER, D., ŠEBEKOVÁ, K., SCHINZEL, R., VOELKER, W., HEIDLAND, A., & THORNALLEY, P. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1333.083 · Cited by 26
Influence of the inflammatory response on treatment of hepatitis C with triple therapy
Winckler, F. C., Braz, A. M. M., Silva, V. N. D., Golim, M. D. A., Andrade, V. G. D., Machado, P. E. D. A., Silveira, L. V. D. A., & Silva, G. F. (2018) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0137-2018 · Cited by 2
Metadata
- Authors
- Nelson, D. R., Tu, Z., Soldevila-Pico, C., Abdelmalek, M., Zhu, H., Xu, Y. L., Cabrera, R., Liu, C., & Davis, G. L.
- Venue
- Hepatology
- Published
- 2003-10
- Volume
- 38
- Issue
- 4
- Pages
- 859-868
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2027537159
- Cited by
- 202
- References
- 3
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.